Global Markets Direct’s, 'Blood Coagulation - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Blood Coagulation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Blood Coagulation. Blood Coagulation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Blood Coagulation. - A review of the Blood Coagulation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Blood Coagulation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Blood Coagulation. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Blood Coagulation pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Blood Coagulation - Pipeline Review, H1 2013 Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Blood Coagulation Overview 6 Therapeutics Development 7 An Overview of Pipeline Products for Blood Coagulation 7 Blood Coagulation Therapeutics under Development by Companies 9 Blood Coagulation Therapeutics under Investigation by Universities/Institutes 10 Late Stage Products 11 Comparative Analysis 11 Mid Clinical Stage Products 12 Comparative Analysis 12 Discovery and Pre-Clinical Stage Products 13 Comparative Analysis 13 Blood Coagulation Therapeutics - Products under Development by Companies 14 Blood Coagulation Therapeutics - Products under Investigation by Universities/Institutes 15 Companies Involved in Blood Coagulation Therapeutics Development 16 Bayer AG 16 Endotis Pharma 17 ARCA biopharma, Inc. 18 China Biologic Products, Inc. 19 PepTx, Inc. 20 Blood Coagulation - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 rivaroxaban - Drug Profile 26 Product Description 26 Mechanism of Action 26 RandD Progress 26 fondaparinux sodium - Drug Profile 30 Product Description 30 Mechanism of Action 30 RandD Progress 30 NU-172 - Drug Profile 31 Product Description 31 Mechanism of Action 31 RandD Progress 31 Human Prothrombin Complex Concentrate - Drug Profile 33 Product Description 33 Mechanism of Action 33 RandD Progress 33 PTX-003 - Drug Profile 34 Product Description 34 Mechanism of Action 34 RandD Progress 34 NAVOH-002 - Drug Profile 35 Product Description 35 Mechanism of Action 35 RandD Progress 35 DIS-COM-COAG - Drug Profile 36 Product Description 36 Mechanism of Action 36 RandD Progress 36 Recombinant Simukunin - Drug Profile 37 Product Description 37 Mechanism of Action 37 RandD Progress 37 Vicagrel - Drug Profile 38 Product Description 38 Mechanism of Action 38 RandD Progress 38 Factor XIa Inhibitors - Drug Profile 39 Product Description 39 Mechanism of Action 39 RandD Progress 39 Blood Coagulation Therapeutics - Drug Profile Updates 40 Blood Coagulation Therapeutics - Dormant Products 51 Blood Coagulation - Product Development Milestones 52 Featured News and Press Releases 52 Mar 27, 2013: Pozen Submits New Drug Application For PA32540 52 Oct 31, 2012: Asahi Kasei Pharma America Initiates Phase III Clinical Trial For ART-123 In Severe Sepsis Patients With Coagulopathy 53 Jul 04, 2012: Platelet Drug Shows Clinical Benefits For Severe, Unresponsive Aplastic Anemia 53 Feb 28, 2012: Thrombotech Receives FDA Approval For Phase IIa Trial Of THR-18 In US 54 Jun 29, 2011: Kyowa Hakko Kirin Initiates Phase III Clinical Study Of KW-3357 In Japan 54 Nov 15, 2010: Portola Announces Factor Xa Inhibitor Antidote Reverses Anticoagulant Activity Of Factor Xa Inhibitors 55 Apr 29, 2010: Artisan Pharma, Inc. Completes Enrollment In 750-patient Phase IIb Study Of ART-123 In Sepsis Patients With DIC 55 Appendix 57 Methodology 57 Coverage 57 Secondary Research 57 Primary Research 57 Expert Panel Validation 57 Contact Us 58 Disclaimer 58
List of Tables
Number of Products Under Development for Blood Coagulation, H1 2013 7 Products under Development for Blood Coagulation - Comparative Analysis, H1 2013 8 Number of Products under Development by Companies, H1 2013 9 Number of Products under Investigation by Universities/Institutes, H1 2013 10 Comparative Analysis by Late Stage Development, H1 2013 11 Comparative Analysis by Mid Clinical Stage Development, H1 2013 12 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 13 Products under Development by Companies, H1 2013 14 Products under Investigation by Universities/Institutes, H1 2013 15 Bayer AG, H1 2013 16 Endotis Pharma, H1 2013 17 ARCA biopharma, Inc., H1 2013 18 China Biologic Products, Inc., H1 2013 19 PepTx, Inc., H1 2013 20 Assessment by Monotherapy Products, H1 2013 21 Assessment by Stage and Route of Administration, H1 2013 23 Assessment by Stage and Molecule Type, H1 2013 25 Blood Coagulation Therapeutics - Drug Profile Updates 40 Blood Coagulation Therapeutics - Dormant Products 51
List of Figures
Number of Products under Development for Blood Coagulation, H1 2013 7 Products under Development for Blood Coagulation - Comparative Analysis, H1 2013 8 Products under Development by Companies, H1 2013 9 Products under Investigation by Universities/Institutes, H1 2013 10 Late Stage Products, H1 2013 11 Mid Clinical Stage Products, H1 2013 12 Discovery and Pre-Clinical Stage Products, H1 2013 13 Assessment by Monotherapy Products, H1 2013 21 Assessment by Route of Administration, H1 2013 22 Assessment by Stage and Route of Administration, H1 2013 23 Assessment by Molecule Type, H1 2013 24 Assessment by Stage and Molecule Type, H1 2013 25